Identification of protein kinase C beta as a therapeutic target for neuroendocrine prostate cancer and development of a nanoparticle-based therapeutic strategy
暂无分享,去创建一个
Guangjun Nie | Suping Li | Bozhao Li | Zefang Lu | Feilong Qi | Yunkai Qie | Zhouliang Wu | T. Chu | Suying Wu | Zhaoxia Cheng
[1] Na Kong,et al. Synthesis of siRNA nanoparticles to silence plaque-destabilizing gene in atherosclerotic lesional macrophages , 2022, Nature Protocols.
[2] Alan A. Chen,et al. Structural and Binding Effects of Chemical Modifications on Thrombin Binding Aptamer (TBA) , 2021, Molecules.
[3] Yuzhuo Wang,et al. Molecular events in neuroendocrine prostate cancer development , 2021, Nature Reviews Urology.
[4] Yiye Li,et al. Multifunctional biomolecule nanostructures for cancer therapy , 2021, Nature Reviews Materials.
[5] L. M. Valor,et al. Targeting Protein Kinase C in Glioblastoma Treatment , 2021, Biomedicines.
[6] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[7] Jiashu Sun,et al. A DNA origami-based aptamer nanoarray for potent and reversible anticoagulation in hemodialysis , 2021, Nature communications.
[8] A. Shaw,et al. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. , 2020, The New England journal of medicine.
[9] Ying Xu,et al. Molecular identification of protein kinase C beta in Alzheimer's disease , 2020, Aging.
[10] Huile Gao,et al. The progress and perspective of strategies to improve tumor penetration of nanomedicines , 2020 .
[11] F. Ban,et al. Dual-Inhibitors of N-Myc and AURKA as Potential Therapy for Neuroendocrine Prostate Cancer , 2020, International journal of molecular sciences.
[12] Yingfu Li,et al. Evolution of a highly functional circular DNA aptamer in serum , 2020, Nucleic acids research.
[13] E. Sabina,et al. A serine/threonine protein PIM kinase as a biomarker of cancer and a target for anti-tumor therapy. , 2020, Life sciences.
[14] E. Du,et al. TACC3 promotes prostate cancer cell proliferation and restrains primary cilium formation. , 2020, Experimental cell research.
[15] R. Montironi,et al. Epigenetic modulations and lineage plasticity in advanced prostate cancer. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] R. Roskoski. Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update. , 2019, Pharmacological research.
[17] Chunxiao Wu,et al. SOX2 has dual functions as a regulator in the progression of neuroendocrine prostate cancer , 2019, Laboratory Investigation.
[18] T. Graeber,et al. Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies. , 2019, Cancer cell.
[19] Liang Cheng,et al. LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling , 2019, Nature Communications.
[20] P. Laakkonen,et al. Octreotide Conjugates for Tumor Targeting and Imaging , 2019, Pharmaceutics.
[21] Christian M. Metallo,et al. Increased Serine and One-Carbon Pathway Metabolism by PKCλ/ι Deficiency Promotes Neuroendocrine Prostate Cancer. , 2019, Cancer cell.
[22] Jun Zhu,et al. Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma , 2019, Journal of Experimental & Clinical Cancer Research.
[23] Zhihong Zhang,et al. Kinase PIM1 promotes prostate cancer cell growth via c-Myc-RPS7-driven ribosomal stress. , 2019, Carcinogenesis.
[24] K. Noguchi,et al. Protein kinase C alpha-mediated phosphorylation of PIM-1L promotes the survival and proliferation of acute myeloid leukemia cells. , 2018, Biochemical and biophysical research communications.
[25] Kinam Park. Combined therapy of imatinib and an anti-CTLA4 immune-checkpoint inhibitor. , 2018, Journal of controlled release : official journal of the Controlled Release Society.
[26] Michael D. Nyquist,et al. Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. , 2017, Cancer cell.
[27] Elkin Navarro-Quiroz,et al. ELAC (3,12‐di‐O‐acetyl‐8‐O‐tigloilingol), a plant‐derived lathyrane diterpene, induces subventricular zone neural progenitor cell proliferation through PKCβ activation , 2017, British journal of pharmacology.
[28] Henry W. Long,et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance , 2017, Science.
[29] Kaitlyn M. Gayvert,et al. N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. , 2016, Cancer cell.
[30] P. Jurasz,et al. The potential of enzastaurin to enhance platelet aggregation and growth factor secretion: implications for cancer cell survival , 2015, Journal of thrombosis and haemostasis : JTH.
[31] Y. Zhang,et al. The protein kinase C (PKC) inhibitors combined with chemotherapy in the treatment of advanced non-small cell lung cancer: meta-analysis of randomized controlled trials , 2015, Clinical and Translational Oncology.
[32] Jeffrey A Jones,et al. PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL. , 2014, Blood.
[33] S. Szymczak,et al. Genomewide RNAi screen identifies protein kinase Cβ and new members of mitogen‐activated protein kinase pathway as regulators of melanoma cell growth and metastasis , 2014, Pigment cell & melanoma research.
[34] G. Bepler,et al. Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers , 2013, Cancer.
[35] Y. Katayama,et al. Protein kinase C (PKC) isozyme-specific substrates and their design. , 2012, Biotechnology advances.
[36] V. Heinemann,et al. A double‐blind, randomized, placebo‐controlled, phase 2 study of maintenance enzastaurin with 5‐fluorouracil/leucovorin plus bevacizumab after first‐line therapy for metastatic colorectal cancer , 2012, Cancer.
[37] M. Carducci,et al. Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics , 2012, Investigational New Drugs.
[38] A. Ganeshpurkar,et al. Synthesis and evaluation of biodegradable PCL/PEG nanoparticles for neuroendocrine tumor targeted delivery of somatostatin analog , 2012, Drug delivery.
[39] H. Allgayer,et al. Enzastaurin inhibits invasion and metastasis in lung cancer by diverse molecules , 2010, British Journal of Cancer.
[40] O. Franco,et al. Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma , 2010, Oncogene.
[41] S. Knapp,et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases , 2007, Proceedings of the National Academy of Sciences.
[42] C. Collins,et al. SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition. , 2017, European urology.